投资机构Baird宣布将Instil Bio, Inc.的股票评级从"跑赢大盘"下调至"中性",同时将其目标股价从180美元大幅削减至7美元。此次调整主要基于该公司当前的近似现金价值进行重新评估。
分析师指出,此次评级和目标价的双重下调反映了对Instil Bio业务前景的审慎看法。目标价调整为7美元意味着较先前180美元的目标价出现显著缩水,凸显出市场对该生物技术公司价值评估的根本性变化。
投资机构Baird宣布将Instil Bio, Inc.的股票评级从"跑赢大盘"下调至"中性",同时将其目标股价从180美元大幅削减至7美元。此次调整主要基于该公司当前的近似现金价值进行重新评估。
分析师指出,此次评级和目标价的双重下调反映了对Instil Bio业务前景的审慎看法。目标价调整为7美元意味着较先前180美元的目标价出现显著缩水,凸显出市场对该生物技术公司价值评估的根本性变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.